Journal of Adolescent Health
Volume 46, Issue 3 , Pages 209-217 , March 2010

Social and Emotional Impairment in Children and Adolescents with ADHD and the Impact on Quality of Life

  • Peter M. Wehmeier, M.D.

      Affiliations

    • Lilly Deutschland, Medical Department, Bad Homburg, Germany
    • Corresponding Author InformationAddress correspondence to: Peter M. Wehmeier, Lilly Deutschland GmbH, Werner-Reimers-Strasse 2-4, 61352 Bad Homburg, Germany.
    • ,
  • Alexander Schacht, Ph.D.

      Affiliations

    • Lilly Deutschland, Medical Department, Bad Homburg, Germany
    • ,
  • Russell A. Barkley, Ph.D.

      Affiliations

    • Department of Psychiatry, SUNY Upstate Medical School, Syracuse, New York
    • Medical University of South Carolina, Charleston, South Carolina

Received 25 March 2009 ,Accepted 30 September 2009.

References 

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000;
  2. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry. 2003;2:104–112
  3. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948
  4. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237–248
  5. Teicher MH, Andersen SL, Navalta CP, et al. Neuropsychiatric disorders of childhood and adolescence. In:  Yudofsky SC,  Hales RE editor. The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences. Washington, DC: American Psychiatric Publishing; 2002;p. 1069–1119
  6. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992;
  7. Goos LM, Crosbie J, Payne S, et al. Validation and extension of the endophenotype model in ADHD patterns of inheritance in a family study of inhibitory control. Am J Psychiatry. 2009;166:711–717
  8. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Publications; 2008;
  9. Wender PH. Attention-Deficit Hyperactivity Disorder in Adults. Oxford, UK: Oxford University Press; 1998;
  10. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: An overview. Ann N Y Acad Sci. 2001;931:1–16
  11. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood. Results from the National Comorbidity Survey Replication. Biol Psychiatry. 2005;57:1442–1451
  12. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734–1746
  13. Barkley RA. Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd edition. New York, NY: Guilford Press; 2006;
  14. Thompson MJ, Brooke XM, West CA, et al. Profiles, co-morbidity and their relationship to treatment of 191 children with AD/HD and their families. Eur Child Adolesc Psychiatry. 2004;13:234–242
  15. Swanson JM. Role of executive function in ADHD. J Clin Psychiatry. 2003;64(Suppl 14):35–39
  16. Perwien AR, Faries DE, Kratochvil CJ, et al. Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr. 2004;25:264–271
  17. Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005;116:e364–e369
  18. Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-life outcomes?. J Child Adolesc Psychopharmacol. 2006;16:713–724
  19. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl 12):10–15
  20. Nijmeijer JS, Minderaa RB, Buitelaar JK, et al. Attention-deficit/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev. 2008;28:692–708
  21. Escobar R, Hervas A, Soutullo CA, et al. Attention-deficit/hyperactivity disorder: Burden of the disease according to subtypes in recently diagnosed children [Editorial]. Actas Esp Psiquiatr. 2008;36:285–294
  22. Brook U, Boaz M. Attention deficit and hyperactivity disorder (ADHD) and learning disabilities (LD): Adolescents perspective. Patient Educ Couns. 2005;58:187–191
  23. Karande S, Bhosrekar K, Kulkarni M, et al. Health-related quality of life of children with newly diagnosed specific learning disability. J Trop Pediatr. 2009;55:160–169
  24. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with Attention-Deficit/Hyperactivity Disorder: A population-based study. Health Qual Life Outcomes. 2006;4:26
  25. Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: Review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4:183–207
  26. Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002;41:530–537
  27. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114:e541–e547
  28. Matza LS, Rentz AM, Secnik K, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25:166–174
  29. Riley AW, Spiel G, Coghill D, et al. Factors related to Health-Related Quality of Life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):i38–i45
  30. Strine TW, Lesesne CA, Okoro CA, et al. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev Chronic Dis. 2006;3:A52
  31. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(Suppl 1):i2–i7
  32. Thorell LB, Rydell AM. Behaviour problems and social competence deficits associated with symptoms of attention-deficit/hyperactivity disorder: Effects of age and gender. Child Care Health Dev. 2008;34:584–595
  33. Coghill D, Soutullo C, d'Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health. 2008;28(2):31
  34. Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry. 2009;50:335–342
  35. Rosenberg M. Society and the Adolescent Self-Image. Princeton, NJ: Princeton University Press; 1965;
  36. Becker K, Wehmeier PM, Schmidt MH. The Noradrenergic Transmitter System in ADHD. Principles and Implications for Treatment. Stuttgart, Germany: Thieme; 2006;
  37. Klimkeit I, Graham C, Lee P, et al. Children should be seen and heard. Self-report of feelings and behavior in primary-school-age children with ADHD. J Atten Disord. 2006;10:181–191
  38. Fischer M, Barkley RA, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol. 1990;58:580–588
  39. Pfiffner LJ, McBurnett K, Lahery BB, et al. Association of parental psychopathology to the comorbid disorders of boys with attention-deficit hyperactivity disorder. J Consult Clin Psychol. 1999;67:881–893
  40. Wilens TE, Biederman J, Brown S, et al. Psychiatric comorbidity and functioning in clinically-referred preschool. children and school-age youth with ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:262–268
  41. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:1715–1725
  42. Schreyer I, Hampel P. [ADHD among boys in childhood: quality of life and parenting behavior][Article in German]. Z Kinder Jugendpsychiatr Psychother. 2009;37:69–75
  43. Söderlund G, Sikström S, Smart A. Listen to the noise: Noise is beneficial for cognitive performance in ADHD. J Child Psychol Psychiatry. 2007;48:840–847
  44. Coghill D, Spiel G, Baldursson G, et al. Which factors impact on clinician-rated impairment in children with ADHD?. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):i307
  45. Becker A, Steinhausen HC, Baldursson G, et al. Psychopathological screening of children with ADHD: Strengths and Difficulties Questionnaire in a pan-European study. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):i56–i62
  46. Meltzer H, Gatward R, Goodman R, et al. Mental health of children and adolescents in Great Britain. Int Rev Psychiatry. 2003;15:185–187
  47. Hoza B, Mrug S, Gerdes AC, et al. What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder?. J Consult Clin Psychol. 2005;73:411–423
  48. King CA, Young RD. Peer popularity and peer communication patterns: hyperactive versus active but normal boys. J Abnorm Child Psychol. 1981;9:465–482
  49. Gresham FM, MacMillan DL, Bocian KM, et al. Comorbidity of hyperactivity-impulsivity-inattention and conduct problems: Risk factors in social, affective, and academic domains. J Abnorm Child Psychol. 1998;26:393–406
  50. Braaten EB, Rosén LA. Self-regulation of affect in attention-deficit hyperactivity disorder (ADHD) and non-ADHD boys: Differences in empathic responding. J Consult Clin Psychol. 2000;68:313–321
  51. Melnick SM, Hinshaw SP. Emotion regulation and parenting in AD/HD and comparison boys: Linkages with social behaviors and peer preference. J Abnorm Child Psychol. 2000;28:73–86
  52. Treuting JJ, Hinshaw SP. Depression and self-esteem in boys with attention-deficit/hyperactivity disorder: Associations with comorbid aggression and explanatory attributional mechanisms. J Abnorm Child Psychol. 2001;29:23–39
  53. Hechtman L, Weiss G, Perlman T. Hyperactives as young adults: self-esteem and social skills. Can J Psychiatry. 1980;25:478–483
  54. Alston CY, Romney DM. A comparison of medicated and nonmedicated attention-deficit disordered hyperactive boys. Acta Paedopsychiatr. 1992;55:65–70
  55. Edbom T, Lichtenstein P, Granlund M, et al. Long-term relationships between symptoms of attention deficit hyperactivity disorder and self-esteem in a prospective longitudinal study of twins. Acta Paediatrica. 2006;95:650–657
  56. Tafarodi RW, Swann WB. Self-liking and self-competence as dimensions of global self-esteem: Initial validation of a measure. J Pers Assess. 1995;65:322–342
  57. Tafarodi RW, Swann WB. Two-dimensionsal self-esteem: Theory and measurement. Pers Individ Dif. 2001;31:653–673
  58. Krueger M, Kendall J. Descriptions of self: an exploratory study of adolescents with ADHD. J Child Adolesc Psychiatr Nurs. 2001;14:61–72
  59. Serretti A, Olgiati P, Colombo C. Components of self-esteem in affective patients and non-psychiatric controls. J Affect Disord. 2005;88:93–98
  60. O'Dea JA. Self-concept, self-esteem and body weight in adolescent females: A three-year longitudinal study. J Health Psychol. 2006;11:599–611
  61. Roy MA, Neale MC, Kendler KS. The genetic epidemiology of self-esteem. Br J Psychiatry. 1995;166:813–820
  62. Raevuori A, Dick DM, Keski-Rahkonen A, et al. Genetic and environmental factors affecting self-esteem from age 14 to 17: A longitudinal study of Finnish twins. Psychol Med. 2007;37:1625–1633
  63. Steinhausen HC, Metzke CW, Meier M, et al. Prevalence of child and adolescent psychiatric disorders: The Zurich Epidemiological Study. Acta Psychiatra Scand. 1998;98:262–271
  64. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry. 1999;40:57–87
  65. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry. 2001;42:487–492
  66. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40:147–158
  67. Connor D, Edwards G, Fletcher KE, et al. Correlates of comorbid psychopathology in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:193–200
  68. Steinhausen HC, Nøvik TS, Baldursson G, et al. Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):i25–i29
  69. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children and adolescents. Child Adolesc Psychiatry Ment Health. 2008;2:15
  70. Gioia GA, Isquith PK, Guy SC, et al. BRIEF: Behavior Rating Inventory of Executive Function. Odessa, FL: Psychological Assessment Resources, Inc; 2000;
  71. Lynam DR. Early identification of the fledgling psychopath: Locating the psychopathic child in the current nomenclature. J Abnorm Psychology. 1998;107:566–575
  72. Waschbusch DA. A meta-analytic examination of comorbid hyperactive-impulsive-attention problems and conduct problems. Psychological Bull. 2002;128:118–150
  73. Hoy E, Weiss G, Minde K, et al. The hyperactive child at adolescence: cognitive, emotional and social functioning. J Abnorm Child Psychol. 1978;6:311–324
  74. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;5:437–446
  75. Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: Adolescent and adult long-term outcome. Ment Retard Dev Rehabil Res Rev. 1999;5:243–250
  76. Milich R, Loney J. The role of hyperactivity and aggressive symptomatology in predicting adolescent outcome among hyperactive children. J Pediatr Psychol. 1979;4:93–112
  77. Rubia K, Noorloos J, Smith A, et al. Motor timing deficits in community and clinical boys with hyperactive behavior: the effect of methylphenidate on motor timing. J Abnorm Child Psychol. 2003;31:301–313
  78. Rubia K, Smith AB, Halari R, et al. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. Am J Psychiatry. 2009;166:83–94
  79. Coghill D, Danckaerts M, Sonuga-Barke E, et al. Practitioner review: quality of life in child mental health - Conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50:544–561
  80. Wallander JL, Schmitt M, Koot HM. Quality of life measurements in children and adolescents: Issues, instruments, and applications. J Clin Psychol. 2001;57:571–585
  81. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: A systematic review. Eur Child Adolesc Psychiatry. 2009;[Epub ahead of print]
  82. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2:113–127
  83. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887–900
  84. Landgraf JM, Abetz LN, Ware JE. The CHQ Users Manual. Boston, MA: Health Act; 1999;
  85. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–812
  86. Riley AW, Forrest CB, Rebok GW, et al. The Child Report Form of the CHIP-Child Edition: Reliability and validity. Med Care. 2004;42:221–231
  87. Riley AW, Forrest CB, Starfield B, et al. The Parent Report Form of the CHIP-Child Edition: Reliability and validity. Med Care. 2004;42:210–220
  88. Ravens-Sieberer U, Auquier P, Erhart M, et al. The KIDSCREEN-27 quality of life measure for children and adolescents: Psychometric results from a cross-cultural survey in 13 European countries. Qual Life Res. 2007;16:1347–1356
  89. World Health Organization. International Classification of Functioning, Disability and Health. Geneva, Switzerland: WHO; 2001;
  90. Üstün TB. Using the international classification of functioning, disease and health in attention-deficit/hyperactivity disorder: Separating the disease from its epiphenomena. Ambul Pediatr. 2007;7(Suppl 1):132–139
  91. Topolski TD, Edwards TC, Patrick DL, et al. Quality of life of adolescent males with attention-deficit hyperactivity disorder. J Atten Disord. 2004;7:163–173
  92. Hampel P, Desman C. Stressverarbeitung und Lebensqualität bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Prax Kinderpsychol Kinderpsychiatr. 2006;55:425–443
  93. Hechtman A, Abikoff H, Klein RG, et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:812–819
  94. Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: Effects on quality of life and school functioning. Clin Pediatr (Phila). 2006;45:819–827
  95. Matza LS, Stoeckl MN, Shorr JM, et al. Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoecon Outcomes Res. 2006;6:379–390
  96. Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: Results from a Taiwanese sample. Aust N Z J Psychiatry. 2007;41:998–1004
  97. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23:379–394
  98. Wehmeier PM, Dittmann RW, Schacht A, et al. Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study. J Child Adolesc Psychopharmacol. 2007;17:813–830
  99. Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q. 2008;79:133–137
  100. Hinshaw SP. Impulsivity, emotion regulation, and developmental psychopathology: Specificity versus generality of linkages. Ann N Y Acad Sci. 2003;1008:149–159
  101. Ochsner KN, Gross JJ. The cognitive control of emotion. Trends Cogn Sciences. 2005;9:242–249
  102. Etkin A, Egner T, Peraza DM, et al. Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron. 2006;51:871–882
  103. Berger A, Kofman O, Livneh U, et al. Multidisciplinary perspectives on attention and the development of self-regulation. Prog Neurobiol. 2007;82:256–286
  104. Barkley RA. Adolescents with attention-deficit/hyperactivity disorder: An overview of empirically based treatments. J Psychiatr Pract. 2004;10:39–56
  105. Antshel KM, Barkley R. Psychosocial interventions in attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2008;17:421–437
  106. Taylor E, Sergeant J, Döpfner M, et al. Clinical guidelines for hyperkinetic disorder. European Child Adolesc Psychiatry. 1998;7:184–200
  107. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073–1086
  108. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088–1096
  109. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22:60–73
  110. Evans SW, Pelham WE, Smith BH, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001;9:163–175
  111. Smith BH, Waschbusch DA, Willoughby MT, et al. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev. 2000;3:243–267
  112. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents. Meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007;194:197–209
  113. Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine?. J Am Acad Child Adolesc Psychiatry. 2006;45:149–157
  114. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry. 2006;15:476–495
  115. Wehmeier PM, Schacht A, Lehmann M, et al. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective. Child Adolesc Psychiatry Ment Health. 2008;2:10
  116. Flapper BC, Schoemaker MM. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Dev Med Child Neurol. 2008;50:294–299
  117. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:253–263
  118. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28:402–418
  119. Spencer TJ, Landgraf JM, Adler LA, et al. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: Results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:1766–1775
  120. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113(3 Pt 1):e206–e216
  121. Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61:694–699
  122. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: Supporting details. J Atten Disord. 2008;12(1):15–43
  123. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): Part I: Executive summary. J Atten Disord. 2008;12(1):4–14
  124. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149:112–119

 All authors contributed equally to this work.

PII: S1054-139X(09)00378-4

doi: 10.1016/j.jadohealth.2009.09.009

Journal of Adolescent Health
Volume 46, Issue 3 , Pages 209-217 , March 2010

Article Tools